These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 16735934

  • 1. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [Abstract] [Full Text] [Related]

  • 2. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 3. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD.
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [Abstract] [Full Text] [Related]

  • 4. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A, Glover SJ, Eastell R.
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 12. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.
    Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
    [Abstract] [Full Text] [Related]

  • 13. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators.
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [Abstract] [Full Text] [Related]

  • 14. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
    Schaefers M, Muysers C, Alexandersen P, Christiansen C.
    Menopause; 2009 Sep; 16(3):559-65. PubMed ID: 19423999
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Raloxifene: results from the MORE study.
    Agnusdei D, Iori N.
    J Musculoskelet Neuronal Interact; 2000 Dec; 1(2):127-32. PubMed ID: 15758505
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.
    Arch Intern Med; 2004 Apr 26; 164(8):871-9. PubMed ID: 15111373
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar 26; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.